TY - JOUR
T1 - Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model
AU - Crossley, Rachel A.
AU - Matz, Alyssa
AU - Terry, D. E.W.
AU - Kalinauskas, Ashley
AU - Faucette, Nicole
AU - Poff, Brad
AU - Silbart, Lawrence K.
AU - Suckow, Mark A.
N1 - Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.
PY - 2019/4
Y1 - 2019/4
N2 - Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.
AB - Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.
KW - Autologous vaccine
KW - Cancer immunotherapy
KW - Dog
KW - Model
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85064488179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064488179&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13275
DO - 10.21873/anticanres.13275
M3 - Article
C2 - 30952708
AN - SCOPUS:85064488179
SN - 0250-7005
VL - 39
SP - 1699
EP - 1703
JO - Anticancer Research
JF - Anticancer Research
IS - 4
ER -
